DelveInsight’s, “Liver Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Liver Cancer Pipeline Report
- DelveInsight’s Liver Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
- The leading companies working in the Liver Cancer market include Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others.
- Promising Liver Cancer Pipeline Therapies in the various stages of development include Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.
- November 2023: Hoffmann-La Roche announced a study of Phase 1 & 2 clinical trials for Atezolizumab, Bevacizumab, Tiragolumab and Tocilizumab. This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
- November 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab. This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence.
- November 2023: Bayer announced a study of Phase 2 clinical trials for Pembrolizumab and Regorafenib (Stivarga, BAY73-4506). An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors.
- October 2023: Roswell Park Cancer Institute announced a study of Phase 1 & 2 clinical trials for Sorafenib Tosylate and Pembrolizumab. This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
Request a sample and discover the recent advances in Liver Cancer Treatment Drugs @ Liver Cancer Pipeline Report
In the Liver Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liver Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Liver Cancer Overview
Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide.
Find out more about Liver Cancer Therapeutics Assessment @ Liver Cancer Preclinical and Discovery Stage Products
Liver Cancer Emerging Drugs Profile
- SRF388: Surface Oncology
- MTL-CEBPA: MiNA Therapeutics
- APX3330: Ocuphire Pharma
- Fostroxacitabine bralpamide: Medivir
- CDX-527: Celldex Therapeutics
Liver Cancer Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies Liver Cancer. The Liver Cancer companies which have their Liver Cancer drug candidates in the most advanced stage, i.e. phase III include, Polaris Group.
DelveInsight’s Liver Cancer Pipeline Report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
Liver Cancer Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Immunotherapy
Learn more about the emerging Liver Cancer Pipeline Therapies @ Liver Cancer Clinical Trials Assessment
Scope of the Liver Cancer Pipeline Report
- Coverage- Global
- Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Liver Cancer Companies- Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others.
- Liver Cancer Pipeline Therapies- Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.
Dive deep into rich insights for new drugs for Liver Cancer Treatment, Visit @ Liver Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Liver Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Liver Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ADI-PEG20: Polaris Group
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Brivanib alaninate: ZAI Lab
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ABSK 011: Abbisko Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Liver Cancer Key Companies
- Liver Cancer Key Products
- Liver Cancer- Unmet Needs
- Liver Cancer- Market Drivers and Barriers
- Liver Cancer- Future Perspectives and Conclusion
- Liver Cancer Analyst Views
- Liver Cancer Key Companies
- Appendix
For further information on the Liver Cancer Pipeline therapeutics, reach out to Liver Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/liver-fibrosis-market